AstraZeneca reported robust financial and pipeline results for the first nine months and third quarter of 2025, achieving an 11% increase in total revenue to $43.2 billion at constant exchange rates, with notable double-digit growth across all therapy areas, especially Oncology (up 16%) and Respiratory & Immunology (up 13%). The company’s core operating profit climbed 13%, while core EPS rose 15% year-on-year to $7.04. AstraZeneca highlighted its pipeline momentum, announcing 16 positive Phase III readouts so far in 2025 alongside 31 major regulatory approvals, including advances in hypertension and breast cancer therapy.
The quarter also saw transformative business developments: AstraZeneca finalized its share listing harmonization for global investors, broke ground on a $4.5 billion Virginia manufacturing facility as part of a $50 billion US expansion plan, and entered a historic agreement with the US government to lower prescription drug costs. Additionally, the company acquired Switzerland-based SixPeaks Bio to bolster its obesity R&D pipeline and simplified its Koselugo partnership with Merck. AstraZeneca reaffirmed its FY2025 guidance, projecting total revenue to rise at a high single-digit percentage and core EPS by a low double-digit percentage, driven by continued commercial strength and pipeline delivery.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!